Lehmann E, Klieser E, Klimke A, Krach H, Spatz R
Psychiatric Clinic, University of Düsseldorf, FRG.
Pharmacopsychiatry. 1989 Nov;22(6):258-62. doi: 10.1055/s-2007-1014611.
The therapeutical efficacy of Cavain should be proved in the treatment of patients suffering from abnormal anxiety, psychosomatic complaints and psychoreactive disorder. Thus two randomized groups of patients (26 each) were treated in double-blind technique with either 2 x 200 mg daily Cavain or placebo for a period of 28 days. Prior to the beginning of the investigations and within 14 days intervals the Hamilton Anxiety Scale (HAMA) and the Adjective Check List (Janke and Debus) were applied. The global therapeutical improvement and compatibility were documented after 14 and 28 days. A significant superiority of Cavain in comparison to placebo could be found. Cavain acted anxiolytically and promotive on the subjective vitality-related performance. Therapeutical conclusions are discussed.
卡瓦因（Cavain）在治疗异常焦虑、心身疾病主诉和心理反应性障碍患者方面的治疗效果应得到证实。因此，两组各26名患者采用双盲技术，一组每日服用2×200毫克卡瓦因，另一组服用安慰剂，为期28天。在研究开始前及每间隔14天应用汉密尔顿焦虑量表（HAMA）和形容词检查表（扬克和德布斯）。在第14天和第28天后记录总体治疗改善情况和耐受性。与安慰剂相比，卡瓦因具有显著优势。卡瓦因具有抗焦虑作用，并能促进与主观活力相关的表现。文中对治疗结论进行了讨论。
